Aminosterol Structural Modifications for Longer Half-Life and Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing aminosterol compounds face challenges in improving pharmacokinetic properties while maintaining biological activities, necessitating the development of modifications that enhance pharmacokinetic half-life and potency without altering their intended pharmacological activity.
Innovation Solution
Development of aminosterol compounds with specific structural modifications, such as varying R1, R2, R3, and R4 groups, to increase pharmacokinetic half-life and potency, including the use of pharmaceutically acceptable salts, esters, and stereoisomers, while preserving biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If structural modifications are made to aminosterol compounds, then pharmacokinetic half-life is improved, but biological activity may be altered
Solution Approach 1:
The patent applies parameter changes by systematically modifying specific positions in the aminosterol molecular structure (positions 24, 25, 26, 27) while keeping the core steroid backbone intact. This allows optimization of pharmacokinetic properties through controlled structural variation without fundamentally altering the molecule's biological recognition elements, thereby extending half-life while preserving activity.
Solution Approach 2:
The invention employs local quality by making targeted modifications at specific locations (R1-R4 substituents and stereochemical centers) rather than global structural changes. This localized approach enables fine-tuning of metabolic stability and half-life while maintaining the essential pharmacophore regions that confer biological activity.
2Power
If structural modifications are made to aminosterol compounds, then potency is improved, but pharmacological activity may be altered
Solution Approach 1:
The patent utilizes parameter changes to optimize potency by varying substituents at positions 24-27 and adjusting stereochemistry. These controlled modifications enhance the molecule's affinity and selectivity for its target while preserving the core structural features necessary for the intended pharmacological effect.
Solution Approach 2:
The invention applies dynamics by creating a series of analogs with varying degrees of substitution and stereochemical configurations. This dynamic exploration of chemical space allows identification of structures with enhanced potency while systematically assessing preservation of pharmacological activity across the series.
3Reliability
If natural aminosterols are used, then biological activity is maintained, but pharmacokinetic half-life is limited
Solution Approach 1:
The patent addresses this contradiction by introducing systematic parameter changes to the natural aminosterol structure, specifically at the D-ring region (positions 24-27). These modifications enhance metabolic stability and extend half-life while the core steroid structure and key functional groups are preserved to maintain biological activity.
Solution Approach 2:
The invention extracts the essential pharmacophore elements from the natural aminosterol structure and separates them from the metabolically vulnerable regions. By modifying or removing specific labile groups while retaining the core active structure, the patent achieves extended half-life without sacrificing biological activity.
Data Source
AI summary
Provided herein are aminosterol compounds with modified pharmacokinetic profiles. Also provided herein are methods of treating disease, such as obesity, equine laminitis, equine metabolic syndrome, or cancer with the aminosterol compounds.